文献速递淋巴瘤造血干细胞移植与细胞治疗

非清髓异基因移植治疗皮肤T细胞淋巴瘤获临床与分子缓解

Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

该2期研究纳入35例晚期蕈样肉芽肿(MF)或Sézary综合征(SS)患者,采用全身皮肤电子束、全淋巴照射及抗胸腺细胞球蛋白预处理后行非清髓异基因移植。

要点

  • 非清髓异基因移植可使晚期MF/SS患者获得持久临床与分子缓解。
  • 移植后分子缓解与疾病进展或复发风险显著降低相关。
  • ≥65岁患者移植后临床结局与年轻患者相似。

核心结论

  • 非清髓异基因移植是晚期MF/SS潜在可治愈的替代方案。

研究设计与样本

  • 2期研究,35例(13例MF,22例SS)接受计划移植,多数(80%)为IV期且既往多线系统治疗。

主要发现

  • 1年和2年非复发死亡率分别为3%和14%。
  • 2年、3年、5年总生存率分别为68%、62%、56%。
  • ≥65岁患者与年轻患者临床结局相似。

关键数值与推荐

  • 预处理采用全身皮肤电子束、全淋巴照射及抗胸腺细胞球蛋白。
  • 移植物抗宿主病预防采用环孢素或他克莫司联合吗替麦考酚酯。
  • 第+180天2-4级急性GVHD累积发生率16%,2年中/重度慢性GVHD发生率32%。

临床怎么用

  • 对晚期MF/SS可考虑非清髓异基因移植,移植后行T细胞受体高通量测序监测分子残留。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The majority of patients with refractory, advanced-stage mycosis fungoides (MF) or Sézary syndrome (SS) have a life expectancy of <5 years. Here, we report a phase 2 study of a novel nonmyeloablative allogeneic transplantation strategy tailored for this patient population. This study has completed the enrollment, and 35 patients (13 MF, 22 SS) have undergone transplant as planned. The majority (80%) of the patients had stage IV disease and received multiple previous systemic therapies. All patients had active disease at the time of conditioning using total skin electron beam therapy, total lymphoid irradiation, and antithymocyte globulin, and received allograft infusion as outpatients. Cyclosporine or tacrolimus and mycophenolate mofetil were used for graft-versus-host disease (GVHD) prophylaxis. Patients tolerated the transplant well, with 1- and 2-year nonrelapse mortality of 3% and 14%, respectively. The day +180 cumulative incidence of grade 2 to 4 acute GVHD was 16%, and the 2-year incidence of moderate/severe chronic GVHD was 32%. With a median posttransplant follow-up of 5.4 years, the 2-, 3-, and 5-year overall survival rates were 68%, 62%, and 56%. Using high-throughput sequencing of the T-cell receptor for minimal residual disease monitoring, we observed that 43% achieved molecular remission, which was associated with a lower incidence of disease progression or relapse (9% vs 87%; P = .02). Our study also showed that patients who were aged ≥65 years at the time of allotransplant had similar clinical outcomes compared with younger patients. Thus, we have developed an alternative and potentially curative nonmyeloablative allogeneic transplant regimen for patients with advanced stage MF/SS. This trial was registered at www.clinicaltrials.gov as #NCT00896493.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Weng WK, Arai S, Rezvani A, et al. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv. 2020. PMID: 32941647. doi:10.1182/bloodadvances.2020001627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。